AXIN2 and colorectal carcinoma: The platform’s validation phase confirmed its analytical reliability by reproducing prior findings from Hispanic/Latino CRC disparity studies, specifically the enrichment of RNF43 and AXIN2 mutations in EOCRC and the favorable survival associated with WNT pathway alterations.